Trials / Completed
CompletedNCT01948726
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
Multicenter Phase-II-Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- University Hospital Schleswig-Holstein · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible with less lung toxicity in smaller studies. Investigators initiated this multicenter phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer under the hypothesis that the ratio of patients with acute radiogenic toxicity Grad II according NCI-CTCAE amounts maximum 20%.
Detailed description
Hypofractionated radiotherapy of the breast 16 × 2.50 Gy with simultaneous integrated boost to the tumor bed (total dose within the boost volume 16 × 3.00 Gy).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Hypofractionation with simultaneous integrated boost |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2013-09-24
- Last updated
- 2021-08-26
Locations
19 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01948726. Inclusion in this directory is not an endorsement.